Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Empagliflozin - Boehringer Ingelheim/Eli Lilly and Company

Drug Profile

Empagliflozin - Boehringer Ingelheim/Eli Lilly and Company

Alternative Names: BI-10773; Jardiance; Oboravo

Latest Information Update: 25 Jan 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Boehringer Ingelheim
  • Developer Boehringer Ingelheim; Duke Clinical Research Institute; Eli Lilly and Company; Kobe University; Medical University of Vienna; Mount Sinai Hospital (Toronto); University of Oxford; Yale University
  • Class Antihyperglycaemics; Benzhydryl compounds; Cardiovascular therapies; Chlorinated hydrocarbons; Cyclic ethers; Glucosides; Heart failure therapies; Small molecules; Urologics
  • Mechanism of Action Sodium-glucose transporter 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Cardiovascular disorders; Chronic heart failure; Renal failure; Type 2 diabetes mellitus
  • Phase III Acute heart failure; Gestational diabetes; Heart failure; Insulin resistance; Type 1 diabetes mellitus
  • Phase II Decompensated heart failure; Kidney disorders

Most Recent Events

  • 23 Jan 2024 Registered for Renal failure in Canada (PO)
  • 05 Nov 2023 Boehringer Ingelheim completes a phase III EMPACT-MI trial in Acute heart failure in USA, Ukraine, Spain, Serbia, Russia, Romania, Poland, Netherlands, South Korea, Japan, Israel, India, Hungary, Germany, France, Denmark, China, Canada, Bulgaria, Brazil, Australia, Argentina (PO) (NCT04509674)
  • 03 Nov 2023 Efficacy and adverse events data from a phase II trial in Renal failure released by Boehringer Ingelheim
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top